Malignant gliomas are largely resistant to current chemotherapeutic strategies often displaying a multidrug-resistant phenotype. Mechanisms involved in drug resistance are reduced cellular
drug accumulation through membrane efflux pumps,
drug detoxification as well as alterations in
drug target specificity. In 27 primary and 17 secondary
glioblastomas and their astrocytic precursor
tumors, we studied the immunohistochemical expression profile of
P-glycoprotein (P-gp),
multidrug resistance-associated protein (MRP), lung resistance-related
protein (LRP),
metallothionein, and
topoisomerase II alpha. Glial
tumor cells in all
glioblastomas showed constant up-regulation of LRP, MRP, and
topoisomerase II alpha. P-gp was found in 90% of the primary and 60% of the secondary
glioblastomas. In precursor
tumors, these drug resistance-related factors were expressed in varying proportions.
Metallothionein, also found in normal and activated astrocytes, was retained in all neoplastic phenotypes. Furthermore,
metallothionein, P-gp, LRP, and
topoisomerase II alpha were strongly expressed by normal and neoplastic vessels which may confer to impaired penetration of therapeutic agents through the blood-brain and blood-
tumor barrier. However, the expression profiles of drug resistance-related
proteins neither differed between primary and secondary
glioblastomas nor revealed any correlation to precursor or recurrent
tumors. Nevertheless, inhibition of these factors may be promising approaches to the management of
malignant gliomas.